Sex-specifics of ECT outcome.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
01 04 2023
Historique:
received: 02 03 2022
revised: 23 12 2022
accepted: 25 12 2022
pubmed: 13 1 2023
medline: 25 2 2023
entrez: 12 1 2023
Statut: ppublish

Résumé

Electroconvulsive therapy (ECT) is the most effective treatment for patients with severe major depressive disorder (MDD). Given the known sex differences in MDD, improved knowledge may provide more sex-specific recommendations in clinical guidelines and improve outcome. In the present study we examine sex differences in ECT outcome and its predictors. Clinical data from 20 independent sites participating in the Global ECT-MRI Research Collaboration (GEMRIC) were obtained for analysis, totaling 500 patients with MDD (58.6 % women) with a mean age of 54.8 years. Severity of depression before and after ECT was assessed with validated depression scales. Remission was defined as a HAM-D score of 7 points or below after ECT. Variables associated with remission were selected based on literature (i.e. depression severity at baseline, age, duration of index episode, and presence of psychotic symptoms). Remission rates of ECT were independent of sex, 48.0 % in women and 45.7 % in men (X The evidence provided by our study suggests that ECT as a biological treatment for MDD is equally effective in women and men. A shorter duration of index episode was an additional sex- specific predictor for remission in women. Future research should establish whether the confidence intervals for the corresponding predictive margins are overlapping, as we find, or not.

Identifiants

pubmed: 36632848
pii: S0165-0327(22)01507-5
doi: 10.1016/j.jad.2022.12.144
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

243-248

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Conflict of interest R.R. received funding from Innovative Medical Research [RE111722 to RR] and German Research Foundation (DFG, grant RE4458/1-1 to RR). U.D. received funding from German Research Foundation #8 FOR2107 DA1151/5-1 and DA1151/5-2 to UD. L.O. received funding from Western Norway Regional Health Authority Grant Nos. 911986 and 912238. A.K. Aki is supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP21dm0307102h0003. L.E. received the Research Foundation Flanders (FWO) grant G0C0319N, KU Leuven Research Fund C24/18/095 and the Sequoia Fund for Research on Ageing and Mental Health. P.P. received MH125126 and MH111826. M.K. received a lecture fee by Innomed Medizintechnik in 2017 & 2018 GW received funding from the Brain Foundation of the Netherlands (Hersenstichting). There are no further conflicts of interest.

Auteurs

M A J T Blanken (MAJT)

Psychiatry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; Amsterdam UMC, location Vumc, Amsterdam, the Netherlands. Electronic address: m.blanken@ggzingeest.nl.

M L Oudega (ML)

GGZ inGeest Specialized Mental Health Care, Amsterdam, the Netherlands; Psychiatry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; Psychiatry, Amsterdam Public Health (Research Institute), Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; Amsterdam UMC, location Vumc, Amsterdam, the Netherlands.

A W Hoogendoorn (AW)

GGZ inGeest Specialized Mental Health Care, Amsterdam, the Netherlands; Psychiatry, Amsterdam Public Health (Research Institute), Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; Amsterdam UMC, location Vumc, Amsterdam, the Netherlands.

C S Sonnenberg (CS)

Psychiatry, Amsterdam Public Health (Research Institute), Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; GGZ Parnassia NH, Specialized Mental Health Care, Castricum, the Netherlands.

D Rhebergen (D)

Psychiatry, Amsterdam Public Health (Research Institute), Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; Amsterdam UMC, location Vumc, Amsterdam, the Netherlands; GGZ Centraal, Specialized Mental Health Care, Amersfoort, the Netherlands.

U M H Klumpers (UMH)

GGZ inGeest Specialized Mental Health Care, Amsterdam, the Netherlands; Psychiatry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; Psychiatry, Amsterdam Public Health (Research Institute), Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; Amsterdam UMC, location Vumc, Amsterdam, the Netherlands.

L Van Diermen (L)

Psychiatric Center Bethanië, Andreas Vesaliuslaan 39, 2980 Zoersel, Belgium; Department of Biomedical Sciences, Collaborative Antwerp Psychiatric Research Institute (CAPRI), Faculty of Medicine and Health Sciences, University of Antwerp. Universiteitsplein 1, 2610 Antwerp, Belgium; University Psychiatric Center (UPC) Duffel, Stationsstraat 22c, 2570 Duffel, Belgium.

T Birkenhager (T)

Department of Biomedical Sciences, Collaborative Antwerp Psychiatric Research Institute (CAPRI), Faculty of Medicine and Health Sciences, University of Antwerp. Universiteitsplein 1, 2610 Antwerp, Belgium; Erasmus MC, Rotterdam, the Netherlands.

D Schrijvers (D)

Department of Biomedical Sciences, Collaborative Antwerp Psychiatric Research Institute (CAPRI), Faculty of Medicine and Health Sciences, University of Antwerp. Universiteitsplein 1, 2610 Antwerp, Belgium; University Psychiatric Center (UPC) Duffel, Stationsstraat 22c, 2570 Duffel, Belgium.

R Redlich (R)

Department of Psychology, University of Halle, Germany; Institute for Translational Psychiatry, University of Münster Germany, Germany.

U Dannlowski (U)

Institute for Translational Psychiatry, University of Münster Germany, Germany.

W Heindel (W)

Department of Radiology, University of Münster Germany, Germany.

M Coenjaerts (M)

Division of Medical Psychology, Department of Psychiatry and Psychotherapy, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.

P Nordanskog (P)

Center for Social and Affective Neuroscience (CSAN), Department of Biomedical and Clinical Sciences, Linköping University, Department of Psychiatry, Linköping University Hospital, Sweden.

L Oltedal (L)

Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway.

U Kessler (U)

Department of Clinical Medicine, University of Bergen, Bergen, Norway; NORMENT, Division of Psychiatry, Haukeland University Hospital, Bergen, Norway.

L M Frid (LM)

Department of Clinical Medicine, University of Bergen, Bergen, Norway.

A Takamiya (A)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Hills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of Medicine, Tokyo, Japan; Neuropsychiatry, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Belgium.

T Kishimoto (T)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Hills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of Medicine, Tokyo, Japan.

M B Jorgensen (MB)

Psychiatric Centre Copenhagen and Institute of Clinical Medicine, University of Copenhagen, Denmark.

A Jorgensen (A)

Psychiatric Centre Copenhagen and Institute of Clinical Medicine, University of Copenhagen, Denmark.

T Bolwig (T)

Psychiatric Centre Copenhagen and Institute of Clinical Medicine, University of Copenhagen, Denmark.

L Emsell (L)

Neuropsychiatry, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Belgium.

P Sienaert (P)

Academic Center for ECT and Neuromodulation (AcCENT), University Psychiatric Center (UPC) - KU Leuven, Kortenberg, Belgium.

F Bouckaert (F)

Neuropsychiatry, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Belgium.

C C Abbott (CC)

University of New Mexico Department of Psychiatry, 87131, United States of America.

P Péran (P)

ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France.

C Arbus (C)

Service de Psychiatrie et de Psychologie Médicale, Centre Expert Dépression Résistante FondaMental, CHU Toulouse, Hospital Purpan, ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France.

A Yrondi (A)

Service de Psychiatrie et de Psychologie Médicale, Centre Expert Dépression Résistante FondaMental, CHU Toulouse, Hospital Purpan, ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France.

M Kiebs (M)

Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany; Section of Medical Psychology, University of Bonn, Bonn, Germany; School of Medicine & Health Sciences University Hospital Oldenburg at the Karl-Jaspers Clinic, Germany.

A Philipsen (A)

Section of Medical Psychology, University of Bonn, Bonn, Germany.

J A van Waarde (JA)

Rijnstate Arnhem, the Netherlands.

E Prinsen (E)

Rijnstate Arnhem, the Netherlands.

M van Verseveld (M)

Rijnstate Arnhem, the Netherlands.

G Van Wingen (G)

Amsterdam UMC, location University of Amsterdam, Department of Psychiatry, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Neuroscience, Amsterdam, the Netherlands.

F Ten Doesschate (F)

Rijnstate Arnhem, the Netherlands; Amsterdam UMC, location University of Amsterdam, Department of Psychiatry, Meibergdreef 9, Amsterdam, the Netherlands.

J A Camprodon (JA)

Division of Neuropsychiatry, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America.

M Kritzer (M)

Division of Neuropsychiatry, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America.

T Barbour (T)

Massachusetts General Hospital, United States of America.

M Argyelan (M)

Institute of Behavioral Science, Feinstein Institutes for Medical Research, Manhasset, NY, United States of America.

N Cardoner (N)

Sant Pau Mental Health Research Group, Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Psychiatry and Forensic Medicine, School of Medicine Bellaterra, Universitat Autònoma de Barcelona, Barcelona, Spain; CIBERSAM, Carlos III Health Institute, Madrid, Spain.

M Urretavizcaya (M)

CIBERSAM, Carlos III Health Institute, Madrid, Spain; Bellvitge Biomedical Research Institute-IDIBELL, Department of Psychiatry, Bellvitge University Hospital, Barcelona, Spain; Department of Clinical Sciences, Bellvitge Campus, Universitat de Barcelona-UB, Barcelona, Spain.

C Soriano-Mas (C)

CIBERSAM, Carlos III Health Institute, Madrid, Spain; Bellvitge Biomedical Research Institute-IDIBELL, Department of Psychiatry, Bellvitge University Hospital, Barcelona, Spain; Department of Social Psychology and Quantitative Psychology, Universitat de Barcelona-UB, Barcelona, Spain.

K L Narr (KL)

Department of Neurology, Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, United States of America.

R T Espinoza (RT)

Department of Neurology, Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, United States of America.

J Prudic (J)

Columbia University Irving Medical Center, United States of America.

S Rowny (S)

Columbia University Irving Medical Center, United States of America.

Ph van Eijndhoven (P)

Radboud University, Nijmegen, the Netherlands.

I Tendolkar (I)

Radboud University, Nijmegen, the Netherlands.

A Dols (A)

Psychiatry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; Amsterdam UMC, location Vumc, Amsterdam, the Netherlands; Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH